Here are three things to know.
1. The FDA first approved Lynparza to treat certain types of ovarian cancer in 2014. The drug may now be used to treat breast cancer patients with metastasized tumors that carry a specific BRCA gene mutation.
- This indication makes Lynparza the first drug in its class approved to treat breast cancer, and the first drug ever approved to treat metastatic breast cancer patients with a BRCA gene mutation.
- The FDA also expanded approval for BRACAnalysis CDx, a genetic test developed by Myriad Genetic Laboratories, to help clinicians identify patients who will benefit from treatment with Lynparza.
More articles on supply chain:
Stanford Blood Center faces critical shortage of blood, notes the flu is keeping potential donors away
Demand surges for radiation antidote after Trump’s nuclear button tweet
FDA approves Tamiflu generic: 3 things to know
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
